Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation

Tumori

Volumn 102, Issue 1, 2016, Pages 65-70

  Osborn, Virginia Wedell ^a,b   Chen, Shan Chin ^a,b   Weiner, Joseph ^a,b   Schwartz, David ^a,b   Schreiber, David ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

African American; Anticoagulation; Aspirin; Prostate cancer; Race; Radiation

Indexed keywords

ACETYLSALICYLIC ACID; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

AFRICAN AMERICAN; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FAILURE FREE SURVIVAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIATION DOSE; BLOOD; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FOLLOW UP; MEDICAL RECORD; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASPIRIN; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICAL RECORDS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84962850906     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000424     Document Type: Article

References (20)

1. Elwood PC, Gallagher AM, Duthie G.G., Mur LAJ, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009; 373(9671): 1301-1309.
2. Wang D, Dubois RN Prostaglandins and cancer. Gut. 2006; 55(1):115-122.
3. Stolfi C, De Simone V, Pallone F, Monteleone G. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci. 2013; 14(9):17972-17985.
4. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573):1603-1613.
5. Rothwell PM, Price JF, Fowkes F.G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826): 1602-1612.
6. Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 84(1):e13-e17.
7. Choe KS, Correa D, Jani A.B., Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010; 116(7):1820-1826.
8. Jacobs EJ, Newton CC, Stevens V.L., Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol. 2014; 32(33):3716-3722.
9. Choe KS, Cowan JE, Chan J.M., Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012; 30(28):3540-3544.
10. Jacobs CD, Chun SG, Yan J, et al Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther. 2014; 15(6):699-706.
11. Grönberg H. Prostate cancer epidemiology. Lancet. 2003; 361 (9360):859-864.
12. Hamilton RJ, Aronson WJ, Presti JC Jr, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007; 110(10):2202-2209.
13. Hoffman RM, Gilliland FD, Eley J.W., et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001; 93(5): 388-395.
14. Powell IJ, Dyson G, Land S., et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev. 2013; 22(5):891-897.
15. Farrell J, Petrovics G, McLeod D.G., Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci. 2013; 14(8):15510-15531.
16. Wallace TA, Prueitt RL, Yi M, et al Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008; 68(3):927-936.
17. Allott EH, Howard LE, Cooperberg M.R., et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014; 114(5):661-666.
18. Surapaneni A, Schwartz D, Nwokedi E., Rineer J, Rotman M, Schreiber D. Radiation therapy for clinically localized prostate cancer: long-term results of 469 patients from a single institution in the era of dose escalation. J Cancer Res Ther. 2014; 10(4):951-956.
19. Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009; 17(2):55-67.
20. Langley RE, Wilson RH, Ring A, et al Add-Aspirin trial: a phase III, double blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors. J Clin Oncol. 2014; 32:52 (suppl: abstr TPS 1617).